About PSMA PET/CT Imaging in Prostate Cancer

About PSMA PET/CT Imaging

Characteristics of PSMA

PSMA IS A BIOMARKER IN PROSTATE CANCER^1-4

What makes PSMA an ideal target for imaging and treatment?

PSMA CHARACTERISTIC		WHAT IT MEANS
	PSMA is overexpressed on prostate cancer (PC) cells in >80% of men with PC^5-9	Serves as an actionable biomarker, providing an accessible target for ligand binding^5-9
	Ligands are internalized after binding with PSMA and undergo endocytic recycling^2,3	Facilitates uptake of gallium 68 in PSMA+ cells, including tumor cells^2,3
	PSMA is not appreciably released into circulation, even in patients with progressive disease¹⁰	Facilitates highly specific targeting of PSMA+ lesions¹⁰

CT, computed tomography; PET, positron emission tomography; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.

PSMA PET Imaging in Prostate Cancer

GALLIUM Ga 68 GOZETOTIDE PSMA PET IMAGING HAS BEEN STUDIED IN MULTIPLE TRIALS AND IS APPROVED FOR PATIENTS WITH PROSTATE CANCER^11-14

with suspected metastasis who are candidates for initial definitive therapy¹⁵
with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level¹⁵
who are indicated for PSMA-directed therapy as described in the prescribing information of the therapeutic products¹⁵

If you're considering a PSMA PET/CT scan for your patient, find a LOCAMETZ Scanning Center near you

LOCATE A SCANNING CENTER

References: 1. Davis MI, Bennett MJ, Thomas LM, Bjorkman P. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci U S A. 2005;102(17):5981-5986. 2. Liu H, Rajasekaran AK, Moy P, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 1998;58(18):4055-4060. 3. Rajasaekaran SA, Anilkumar G, Oshima E, et al. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell. 2003;14(12):4835-4845. 4. Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48(2):326-334. 5. Hupe MC, Philippi C, Roth D, et al. Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. Front Oncol. 2018;8:623. 6. Hope TA, Aggarwal R, Chee B, et al. Impact of ⁶⁸Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer. J Nucl Med. 2017;58(12):1956-1961. 7. Minner S, Wittmer C, Graefen M, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate. 2011;71(3):281-288. 8. Pomykala KL, Czernin J, Grogan TR, Armstrong W, Williams J, Calais J. Total-Body ⁶⁸Ga-PSMA-11 PET/CT for bone metastasis detection in prostate cancer patients: potential impact on bone scan guidelines. J Nucl Med. 2020;61(3):405-411. 9. Tsourlakis MC, Klein F, Kluth M, et al. PSMA expression is highly homogenous in primary prostate cancer. Appl Immunohistochem Mol Morphol. 2015;23(6):449-455. 10. Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995;62(5):552-558. 11. Fendler WP, Weber M, Iravani A, et al. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res. 2019;25(24):7448-7454. 12. Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208-1216. 13. Sonni I, Eiber M, Fendler WP, et al. Impact of ⁶⁸Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single-center study. J Nucl Med. 2020;61(8):1153-1160. 14. Fendler WP, Calais J, Eiber M, et al. Assessment of ⁶⁸Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5(6):856-863. 15. Locametz. Prescribing information. Novartis Pharmaceuticals Corp.